SG11202003833TA - Antibody variant and isoform with lowered biological activity - Google Patents
Antibody variant and isoform with lowered biological activityInfo
- Publication number
- SG11202003833TA SG11202003833TA SG11202003833TA SG11202003833TA SG11202003833TA SG 11202003833T A SG11202003833T A SG 11202003833TA SG 11202003833T A SG11202003833T A SG 11202003833TA SG 11202003833T A SG11202003833T A SG 11202003833TA SG 11202003833T A SG11202003833T A SG 11202003833TA
- Authority
- SG
- Singapore
- Prior art keywords
- isoform
- biological activity
- antibody variant
- lowered biological
- lowered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017212179 | 2017-11-01 | ||
| PCT/JP2018/040436 WO2019088143A1 (en) | 2017-11-01 | 2018-10-31 | Antibody variant and isoform with lowered biological activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003833TA true SG11202003833TA (en) | 2020-05-28 |
Family
ID=66331990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003833TA SG11202003833TA (en) | 2017-11-01 | 2018-10-31 | Antibody variant and isoform with lowered biological activity |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20200283544A1 (en) |
| EP (1) | EP3705496A4 (en) |
| JP (2) | JPWO2019088143A1 (en) |
| KR (1) | KR20200074209A (en) |
| CN (1) | CN111479829A (en) |
| AR (1) | AR113816A1 (en) |
| AU (1) | AU2018361430A1 (en) |
| BR (1) | BR112020008393A2 (en) |
| CA (1) | CA3079053A1 (en) |
| CL (1) | CL2020001113A1 (en) |
| CR (1) | CR20200229A (en) |
| IL (1) | IL274265A (en) |
| MA (1) | MA50534A (en) |
| MX (1) | MX2020003472A (en) |
| PE (1) | PE20210553A1 (en) |
| SG (1) | SG11202003833TA (en) |
| TW (1) | TW201930352A (en) |
| WO (1) | WO2019088143A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106519025B (en) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | Method for changing isoelectric point of antibody by using amino acid substitution of CDR |
| TWI505838B (en) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody |
| TWI700300B (en) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII) |
| WO2017115773A1 (en) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Method for promoting efficiency of purification of fc region-containing polypeptide |
| CA3035327A1 (en) | 2016-09-06 | 2018-03-15 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| MX2020003472A (en) | 2017-11-01 | 2020-08-03 | Chugai Pharmaceutical Co Ltd | Antibody variant and isoform with lowered biological activity. |
| TW202340249A (en) * | 2021-12-22 | 2023-10-16 | 日商中外製藥股份有限公司 | Antibody variant with reduced biological activity |
| CN114544839A (en) * | 2022-01-20 | 2022-05-27 | 未名生物医药有限公司 | Charge variant detection method for anti-human nerve growth factor antibody |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| WO2005035753A1 (en) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| AU2003271186A1 (en) | 2003-10-14 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| DK2824183T3 (en) | 2005-04-08 | 2020-09-28 | Chugai Pharmaceutical Co Ltd | Process for the production of bispecific antibodies |
| ES2654040T3 (en) * | 2006-03-31 | 2018-02-12 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for the purification of bispecific antibodies |
| CN101460622A (en) * | 2006-03-31 | 2009-06-17 | 中外制药株式会社 | Antibody modification method for purifying bispecific antibody |
| AU2007294731B2 (en) * | 2006-09-13 | 2014-04-17 | Abbvie Inc. | Cell culture improvements |
| CN106519025B (en) * | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | Method for changing isoelectric point of antibody by using amino acid substitution of CDR |
| TR201802772T4 (en) * | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen binding molecule with alternative function for the function of blood coagulation factor VIII. |
| JP5882913B2 (en) * | 2010-12-27 | 2016-03-09 | 協和発酵キリン株式会社 | Method for preparing aqueous solution containing medium and chelating agent |
| EP2788097A4 (en) | 2011-12-07 | 2015-09-09 | Amgen Inc | IgG2 DISULFIDE ISOFORM SEPARATION |
| GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| EP3280444A4 (en) * | 2015-04-10 | 2019-03-27 | Adimab, LLC | Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species |
| JP6954842B2 (en) * | 2015-12-25 | 2021-10-27 | 中外製薬株式会社 | Antibodies with enhanced activity and methods for modifying them |
| MX2020003472A (en) | 2017-11-01 | 2020-08-03 | Chugai Pharmaceutical Co Ltd | Antibody variant and isoform with lowered biological activity. |
-
2018
- 2018-10-31 MX MX2020003472A patent/MX2020003472A/en unknown
- 2018-10-31 AU AU2018361430A patent/AU2018361430A1/en active Pending
- 2018-10-31 SG SG11202003833TA patent/SG11202003833TA/en unknown
- 2018-10-31 MA MA050534A patent/MA50534A/en unknown
- 2018-10-31 KR KR1020207015464A patent/KR20200074209A/en not_active Application Discontinuation
- 2018-10-31 CR CR20200229A patent/CR20200229A/en unknown
- 2018-10-31 US US16/758,128 patent/US20200283544A1/en active Pending
- 2018-10-31 WO PCT/JP2018/040436 patent/WO2019088143A1/en unknown
- 2018-10-31 EP EP18873627.6A patent/EP3705496A4/en active Pending
- 2018-10-31 BR BR112020008393-3A patent/BR112020008393A2/en unknown
- 2018-10-31 CN CN201880080142.XA patent/CN111479829A/en active Pending
- 2018-10-31 AR ARP180103169A patent/AR113816A1/en unknown
- 2018-10-31 PE PE2020000451A patent/PE20210553A1/en unknown
- 2018-10-31 TW TW107138518A patent/TW201930352A/en unknown
- 2018-10-31 JP JP2019550437A patent/JPWO2019088143A1/en not_active Withdrawn
- 2018-10-31 CA CA3079053A patent/CA3079053A1/en active Pending
-
2020
- 2020-04-27 IL IL274265A patent/IL274265A/en unknown
- 2020-04-27 CL CL2020001113A patent/CL2020001113A1/en unknown
-
2023
- 2023-11-29 JP JP2023202127A patent/JP2024037761A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20210553A1 (en) | 2021-03-17 |
| CA3079053A1 (en) | 2019-05-09 |
| MA50534A (en) | 2020-09-09 |
| AU2018361430A1 (en) | 2020-06-11 |
| RU2020117440A3 (en) | 2022-04-01 |
| BR112020008393A2 (en) | 2020-11-03 |
| CN111479829A (en) | 2020-07-31 |
| RU2020117440A (en) | 2021-12-01 |
| JPWO2019088143A1 (en) | 2020-11-12 |
| MX2020003472A (en) | 2020-08-03 |
| JP2024037761A (en) | 2024-03-19 |
| TW201930352A (en) | 2019-08-01 |
| AR113816A1 (en) | 2020-06-17 |
| KR20200074209A (en) | 2020-06-24 |
| CR20200229A (en) | 2020-07-12 |
| CL2020001113A1 (en) | 2020-11-20 |
| EP3705496A4 (en) | 2021-12-08 |
| WO2019088143A1 (en) | 2019-05-09 |
| IL274265A (en) | 2020-06-30 |
| US20200283544A1 (en) | 2020-09-10 |
| EP3705496A1 (en) | 2020-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274265A (en) | Antibody variant and isoform with lowered biological activity | |
| IL268206A (en) | Bcma-targeting antibody and use thereof | |
| IL272218A (en) | Anti-sirp-alpha antibodies and related methods | |
| ZA202105676B (en) | Anti-trem2 antibodies and related methods | |
| SG10201912199XA (en) | Anti-tim-3 antibodies and use thereof | |
| SG11202005815UA (en) | Bioreactor and related methods | |
| EP3541840C0 (en) | Anti-hla-g antibodies and use thereof | |
| EP3354661A4 (en) | Fully human antibody against human cd137 and use thereof | |
| IL268112A (en) | Anti-tgf-beta antibodies and their use | |
| IL277308A (en) | Anti-hla-g antibodies and use thereof | |
| ZA201605760B (en) | Immobilized proteins and use thereof | |
| GB201602142D0 (en) | Biological methods and materials for use therein | |
| SG10201912366YA (en) | Anti-cd3 antibody and molecules comprising the antibody | |
| IL263242A (en) | Cytosol-penetrating antibody and use thereof | |
| IL282707A (en) | Anti-tim-3 antibodies and their use | |
| IL282708A (en) | Anti-tim-3 antibodies and their use | |
| EP3177320A4 (en) | Human monoclonal antibodies against epha4 and their use | |
| SG11202003585VA (en) | Anti-vista antibody and use thereof | |
| GB201719555D0 (en) | Biosensor device and assembly methods | |
| EP3149046A4 (en) | Humanized anti-cd19 antibody and use thereof | |
| ZA201906248B (en) | Anti-ceacam1 antibody and use thereof | |
| IL286711A (en) | Interleukin-2 variants with modified biological activity | |
| HUE047553T2 (en) | Protein with dextran-saccharase activity, and uses | |
| IL267340A (en) | Anti-pcna monoclonal antibodies and use thereof | |
| GB201709763D0 (en) | Biological materials and methods |